Startseite>>Signaling Pathways>> Neuroscience>> Pain Research>>(±)7(8)-EpDPA

(±)7(8)-EpDPA (Synonyms: (±)7,8-EDP, (±)7,8-EpDPE, (±)7,8-epoxy DPA, (±)7,8-epoxy Docosapentaenoic Acid)

Katalog-Nr.GC41203

Docosahexaenoic acid is the most abundant ω-3 fatty acid in neural tissues, especially in the brain and retina.

Products are for research use only. Not for human use. We do not sell to patients.

(±)7(8)-EpDPA Chemische Struktur

Cas No.: 895127-66-9

Größe Preis Lagerbestand Menge
25μg
57,00 $
Auf Lager
50μg
108,00 $
Auf Lager
100μg
204,00 $
Auf Lager
500μg
904,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Docosahexaenoic acid is the most abundant ω-3 fatty acid in neural tissues, especially in the brain and retina. (±)7(8)-EpDPA is an epoxide derivative of DHA that is generated by the action of cytochrome P450 epoxygenases. It is naturally occurring in plasma and brain and spinal cord tissues and is increased following dietary supplementation with ω-3 fatty acids. (±)7(8)-EpDPA and other epoxy metabolites of DHA modulate receptor and channel activities to evoke diverse effects, such as promoting vasodilation, inhibiting angiogenesis, and decreasing inflammatory and neuropathic pain. (±)7(8)-EpDPA is a substrate of soluble epoxide hydrolase (KM = 15 µM), which converts it to the corresponding diol.

Bewertungen

Review for (±)7(8)-EpDPA

Average Rating: 5 ★★★★★ (Based on Reviews and 21 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for (±)7(8)-EpDPA

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.